GUY YOUNG
- Type
- Physician · Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology
- Where
- BOZEMAN, MT
- NPI
- 1629175195
- Received
- $2,564,190 in 1,632 records, 2019 to 2025 ($2,516,863 general, $47,327 research)
- As principal investigator
- $2,569,889 of research payments to others in 1,376 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 256 | $515,876 |
| 2025 | Research payment | 6 | $4,966 |
| 2024 | General payment | 284 | $463,894 |
| 2024 | Research payment | 6 | $12,130 |
| 2023 | General payment | 410 | $587,249 |
| 2023 | Research payment | 11 | $5,198 |
| 2022 | General payment | 272 | $342,860 |
| 2022 | Research payment | 7 | $5,264 |
| 2021 | General payment | 131 | $194,182 |
| 2021 | Research payment | 1 | $344 |
| 2020 | General payment | 75 | $135,490 |
| 2020 | Research payment | 10 | $17,197 |
| 2019 | General payment | 159 | $277,309 |
| 2019 | Research payment | 4 | $2,224 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 405 | $1,262,856 |
| Consulting Fee | 207 | $758,671 |
| Travel and Lodging | 590 | $390,075 |
| Honoraria | 24 | $74,396 |
| Research payment | 45 | $47,327 |
| Food and Beverage | 341 | $28,606 |
| Compensation for serving as faculty or as a speaker for a medical education program | 1 | $1,213 |
| Education | 15 | $1,031 |
| Gift | 4 | $11 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | BioMarin Pharmaceutical Inc. | $1,368 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | BioMarin Pharmaceutical Inc. | $1,368 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-31 | BioMarin Pharmaceutical Inc. | $1,368 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | GENZYME CORPORATION | $14,104 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-30 | CSL Behring | $6,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-12-23 | Alnylam Pharmaceuticals Inc. | $800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-19 | BioMarin Pharmaceutical Inc. | $1,740 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ROCTAVIAN Drug, Hemophilia A | 2025 | |
| 2025-12-19 | PFIZER INC. | $625 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-12-19 | CSL Behring | $26 | Education | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-12-18 | CSL Behring | $1,184 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-12-18 | CSL Behring | $162 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-12-18 | CSL Behring | $81 | Food and Beverage | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-12-17 | GENZYME CORPORATION | $1,470 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-12-12 | CSL Behring | $2,944 | Consulting Fee | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-12-12 | CSL Behring | $736 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Idelvion Biological, Hematology | 2025 | |
| 2025-12-08 | GENZYME CORPORATION | $500 | Research payment | In-kind items and services | QFITLIA Drug | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inh | 2025 |
| 2025-12-07 | GENZYME CORPORATION | $500 | Research payment | In-kind items and services | QFITLIA Drug | An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fit | 2025 |
| 2025-12-06 | GENZYME CORPORATION | $2,612 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-12-05 | Octapharma USA, Inc. | $3,500 | Honoraria | Cash or cash equivalent | NUWIQ Biological, COAGULATION | 2025 | |
| 2025-12-05 | Octapharma USA, Inc. | $547 | Travel and Lodging | Cash or cash equivalent | NUWIQ Biological, COAGULATION | 2025 | |
| 2025-12-05 | Octapharma USA, Inc. | $107 | Travel and Lodging | Cash or cash equivalent | NUWIQ Biological, COAGULATION | 2025 | |
| 2025-12-05 | Octapharma USA, Inc. | $107 | Travel and Lodging | Cash or cash equivalent | NUWIQ Biological, COAGULATION | 2025 | |
| 2025-12-03 | Novo Nordisk Inc | $10,316 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-03 | Novo Nordisk Inc | $134 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-03 | Novo Nordisk Inc | $43 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-12-02 | Novo Nordisk Inc | $2,292 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-20 | GENZYME CORPORATION | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $666 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $238 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $200 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $153 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $118 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-20 | GENZYME CORPORATION | $118 | Food and Beverage | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-19 | GENZYME CORPORATION | $2,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-11-19 | Genentech, Inc. | $1,520 | Consulting Fee | Cash or cash equivalent | Hemlibra Biological, Hematology | 2025 | |
| 2025-11-19 | PFIZER INC. | $625 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-11-13 | Novo Nordisk Inc | $24 | Food and Beverage | In-kind items and services | Alhemo Drug, Hemophilia | 2025 | |
| 2025-11-10 | HEMA Biologics, LLC | $259 | Travel and Lodging | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | HEMA Biologics, LLC | $124 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | HEMA Biologics, LLC | $122 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | HEMA Biologics, LLC | $71 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | HEMA Biologics, LLC | $56 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | HEMA Biologics, LLC | $33 | Travel and Lodging | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-08 | HEMA Biologics, LLC | $5,000 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-08 | HEMA Biologics, LLC | $4,375 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-08 | HEMA Biologics, LLC | $124 | Travel and Lodging | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-08 | USWM, LLC | $103 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-07 | PFIZER INC. | $625 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-11-07 | HEMA Biologics, LLC | $26 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-06 | CSL Behring | $1,460 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-11-06 | HEMA Biologics, LLC | $329 | Travel and Lodging | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-06 | HEMA Biologics, LLC | $41 | Travel and Lodging | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-05 | HEMA Biologics, LLC | $863 | Travel and Lodging | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-11-04 | PFIZER INC. | $1,875 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-11-04 | PFIZER INC. | $1,250 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-11-04 | GENZYME CORPORATION | $31 | Food and Beverage | In-kind items and services | WAYRILZ Drug, Immunology | 2025 | |
| 2025-11-03 | GENZYME CORPORATION | $250 | Research payment | In-kind items and services | QFITLIA Drug | An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fit | 2025 |
| 2025-11-03 | GENZYME CORPORATION | $250 | Research payment | In-kind items and services | QFITLIA Drug | ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inh | 2025 |
| 2025-10-30 | PFIZER INC. | $1,250 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-10-29 | CSL Behring | $6,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $3,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $1,737 | Travel and Lodging | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $536 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $456 | Travel and Lodging | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $121 | Food and Beverage | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-10-29 | CSL Behring | $120 | Travel and Lodging | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $118 | Travel and Lodging | Cash or cash equivalent | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-10-29 | CSL Behring | $108 | Travel and Lodging | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-29 | CSL Behring | $52 | Travel and Lodging | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $37 | Food and Beverage | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-10-23 | CSL Behring | $664 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-23 | CSL Behring | $473 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-23 | CSL Behring | $123 | Food and Beverage | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-10-20 | Novo Nordisk Health Care AG | $1,310 | Consulting Fee | Cash or cash equivalent | Novoeight Drug, Hemophilia | 2025 | |
| 2025-10-15 | HEMA Biologics, LLC | $875 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-10-14 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | ALPROLIX Biological, Hematology | 2025 | |
| 2025-10-08 | HEMA Biologics, LLC | $1,037 | Travel and Lodging | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-10-08 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | BENEFIX Biological, HEMATOLOGY | 2025 | |
| 2025-10-03 | PFIZER INC. | $625 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-09-29 | PFIZER INC. | $2,500 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-09-26 | Genentech USA, Inc. | $6,970 | Consulting Fee | Cash or cash equivalent | Hemlibra Biological, Hematology | 2025 | |
| 2025-09-26 | Genentech USA, Inc. | $295 | Travel and Lodging | In-kind items and services | Hemlibra Biological, Hematology | 2025 | |
| 2025-09-26 | Genentech USA, Inc. | $118 | Travel and Lodging | Cash or cash equivalent | Hemlibra Biological, Hematology | 2025 | |
| 2025-09-26 | Genentech USA, Inc. | $47 | Food and Beverage | In-kind items and services | Hemlibra Biological, Hematology | 2025 | |
| 2025-09-26 | Genentech USA, Inc. | $47 | Food and Beverage | In-kind items and services | Hemlibra Biological, Hematology | 2025 | |
| 2025-09-26 | Genentech USA, Inc. | $47 | Food and Beverage | In-kind items and services | Hemlibra Biological, Hematology | 2025 | |
| 2025-09-19 | Novo Nordisk Health Care AG | $655 | Consulting Fee | Cash or cash equivalent | Novoeight Drug, Hemophilia | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $1,680 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-09-12 | GENZYME CORPORATION | $4,441 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-09-11 | GENZYME CORPORATION | $14,153 | Consulting Fee | Cash or cash equivalent | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $8,328 | Travel and Lodging | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $783 | Travel and Lodging | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $479 | Food and Beverage | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $63 | Food and Beverage | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $35 | Food and Beverage | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-11 | GENZYME CORPORATION | $25 | Food and Beverage | In-kind items and services | ALTUVIIIO Biological, Hematology | 2025 | |
| 2025-09-10 | GENZYME CORPORATION | $3,484 | Consulting Fee | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-09-10 | HEMA Biologics, LLC | $875 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-09-10 | HEMA Biologics, LLC | $500 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-09-08 | Novo Nordisk Health Care AG | $327 | Consulting Fee | Cash or cash equivalent | Biological, Hemophilia | 2025 | |
| 2025-09-01 | Novo Nordisk Health Care AG | $1,965 | Consulting Fee | Cash or cash equivalent | Biological, Hemophilia | 2025 | |
| 2025-08-28 | Alnylam Pharmaceuticals Inc. | $800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-25 | HEMA Biologics, LLC | $1,750 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-08-25 | Novo Nordisk Health Care AG | $327 | Consulting Fee | Cash or cash equivalent | Biological, Hemophilia | 2025 | |
| 2025-08-23 | GENZYME CORPORATION | $32 | Food and Beverage | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-08-22 | Novo Nordisk Inc | $112 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-22 | Novo Nordisk Inc | $7 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-08-20 | Takeda Pharmaceuticals U.S.A., Inc. | $750 | Consulting Fee | Cash or cash equivalent | CEPROTIN Biological, IMMUNOLOGY | 2025 | |
| 2025-08-15 | PFIZER INC. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $6,713 | Consulting Fee | Cash or cash equivalent | Alhemo Drug, Hemophilia | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $1,187 | Travel and Lodging | In-kind items and services | Alhemo Drug, Hemophilia | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $460 | Travel and Lodging | In-kind items and services | Alhemo Drug, Hemophilia | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $216 | Travel and Lodging | In-kind items and services | Alhemo Drug, Hemophilia | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Alhemo Drug, Hemophilia | 2025 | |
| 2025-08-11 | Novo Nordisk Inc | $23 | Food and Beverage | In-kind items and services | Alhemo Drug, Hemophilia | 2025 | |
| 2025-08-05 | Novo Nordisk Inc | $1,965 | Consulting Fee | Cash or cash equivalent | Alhemo Drug, Hemophilia | 2025 | |
| 2025-07-25 | GENZYME CORPORATION | $5,225 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-18 | CSL Behring | $6,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-07-18 | CSL Behring | $24 | Travel and Lodging | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-07-16 | GENZYME CORPORATION | $871 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-11 | CSL Behring | $748 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-07-11 | CSL Behring | $541 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-07-11 | CSL Behring | $58 | Food and Beverage | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-07-07 | CSL Behring | $2,944 | Consulting Fee | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-06-26 | GENZYME CORPORATION | $12,194 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-24 | GENZYME CORPORATION | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-06-24 | GENZYME CORPORATION | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-06-24 | GENZYME CORPORATION | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-06-24 | GENZYME CORPORATION | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-06-23 | GENZYME CORPORATION | $500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-06-23 | GENZYME CORPORATION | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-06-22 | GENZYME CORPORATION | $6,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-06-22 | F. Hoffmann-La Roche AG | $4,920 | Consulting Fee | Cash or cash equivalent | Hemlibra Biological, Hematology | 2025 | |
| 2025-06-20 | Genentech USA, Inc. | $1,640 | Consulting Fee | Cash or cash equivalent | Hemlibra Biological, Hematology | 2025 | |
| 2025-06-20 | Genentech USA, Inc. | $136 | Food and Beverage | In-kind items and services | Hemlibra Biological, Hematology | 2025 | |
| 2025-06-20 | Novo Nordisk Inc | $125 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-06-20 | CSL Behring | $91 | Food and Beverage | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-06-20 | CSL Behring | $38 | Food and Beverage | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-06-20 | CSL Behring | $34 | Food and Beverage | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-06-19 | CSL Behring | $4,301 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-06-18 | GENZYME CORPORATION | $2,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-06-06 | GENZYME CORPORATION | $3,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $1,441 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $278 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $230 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-06-05 | GENZYME CORPORATION | $99 | Food and Beverage | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-29 | GENZYME CORPORATION | $2,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-22 | CSL Behring | $6,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-22 | GENZYME CORPORATION | $3,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-22 | GENZYME CORPORATION | $184 | Food and Beverage | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-21 | GENZYME CORPORATION | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-21 | GENZYME CORPORATION | $493 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-21 | GENZYME CORPORATION | $340 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-21 | GENZYME CORPORATION | $78 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-19 | Novo Nordisk Health Care AG | $11,327 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-19 | Novo Nordisk Health Care AG | $9,006 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-19 | Novo Nordisk Health Care AG | $745 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-19 | Novo Nordisk Health Care AG | $655 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-19 | Novo Nordisk Health Care AG | $204 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-19 | Novo Nordisk Health Care AG | $31 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-05-09 | CSL Behring | $6,205 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-09 | CSL Behring | $90 | Travel and Lodging | Cash or cash equivalent | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-08 | CSL Behring | $1,493 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-08 | Alnylam Pharmaceuticals Inc. | $800 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-08 | CSL Behring | $743 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-08 | CSL Behring | $190 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-07 | HEMA Biologics, LLC | $5,000 | Honoraria | Cash or cash equivalent | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-05-07 | F. Hoffmann-La Roche AG | $1,733 | Research payment | In-kind items and services | Hemlibra Biological, Hematology | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2025 |
| 2025-05-07 | HEMA Biologics, LLC | $49 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-05-07 | HEMA Biologics, LLC | $38 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-05-07 | HEMA Biologics, LLC | $37 | Food and Beverage | In-kind items and services | SEVENFACT Drug, HEMATOLOGY | 2025 | |
| 2025-05-06 | PFIZER INC. | $720 | Consulting Fee | Cash or cash equivalent | HYMPAVZI Drug, IMMUNOLOGY | 2025 | |
| 2025-05-03 | CSL Behring | $282 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-02 | CSL Behring | $186 | Travel and Lodging | In-kind items and services | HEMGENIX Biological, Hematology | 2025 | |
| 2025-05-01 | GENZYME CORPORATION | $3,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-01 | GENZYME CORPORATION | $3,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-01 | GENZYME CORPORATION | $135 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-05-01 | GENZYME CORPORATION | $9 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-30 | GENZYME CORPORATION | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-30 | GENZYME CORPORATION | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2025 | ||
| 2025-04-30 | GENZYME CORPORATION | $950 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-30 | GENZYME CORPORATION | $771 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-30 | GENZYME CORPORATION | $437 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-30 | GENZYME CORPORATION | $88 | Food and Beverage | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-26 | GENZYME CORPORATION | $10,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-26 | GENZYME CORPORATION | $598 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-26 | GENZYME CORPORATION | $409 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-26 | GENZYME CORPORATION | $270 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-26 | GENZYME CORPORATION | $87 | Travel and Lodging | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-25 | Genentech USA, Inc. | $114 | Food and Beverage | In-kind items and services | Hemlibra Biological, Hematology | 2025 | |
| 2025-04-24 | GENZYME CORPORATION | $25,863 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-24 | GENZYME CORPORATION | $5,559 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-04-21 | GENZYME CORPORATION | $2,940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $10,920 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $622 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $502 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 | |
| 2025-04-16 | GENZYME CORPORATION | $376 | Travel and Lodging | In-kind items and services | QFITLIA Drug, Hematology | 2025 |
The latest 200 records of 1,632.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-11-21 | Genentech, Inc. | Childrens Hospital Los Angeles | $3,622 | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2025 |
| 2025-11-03 | SANOFI US SERVICES INC. | Childrens Hospital Los Angeles | $675 | An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhi | 2025 |
| 2025-10-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $4,860 | NN7415-4307 | 2025 |
| 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Childrens Hospital Los Angeles | $3,050 | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PART | 2025 |
| 2025-10-06 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $105 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2025 |
| 2025-09-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1,170 | NN7415-4307 | 2025 |
| 2025-09-03 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $24,205 | An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fit | 2025 |
| 2025-08-26 | Regeneron Pharmaceuticals, Inc. | Childrens Hospital Los Angeles | $8,100 | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PART | 2025 |
| 2025-08-26 | Regeneron Pharmaceuticals, Inc. | Childrens Hospital Los Angeles | $3,250 | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PART | 2025 |
| 2025-08-26 | Regeneron Pharmaceuticals, Inc. | Childrens Hospital Los Angeles | $3,375 | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PART | 2025 |
| 2025-08-26 | Regeneron Pharmaceuticals, Inc. | Childrens Hospital Los Angeles | $10,000 | A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9 BASED COAGULATION FACTOR IX GENE INSERTION THERAPY IN PART | 2025 |
| 2025-08-25 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $420 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2025 |
| 2025-08-20 | Genentech, Inc. | Childrens Hospital Los Angeles | $1,540 | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2025 |
| 2025-08-11 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $2,244 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2025 |
| 2025-07-09 | CSL Behring | Childrens Hospital Los Angeles | $3,200 | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2025 |
| 2025-07-08 | SANOFI US SERVICES INC. | Childrens Hospital Los Angeles | $71,177 | An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhi | 2025 |
| 2025-06-25 | Novo Nordisk AS | Childrens Hospital Los Angeles | $2,678 | NN7415-4307 | 2025 |
| 2025-06-25 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1,449 | NN7415-4807 | 2025 |
| 2025-06-03 | Genentech, Inc. | Childrens Hospital Los Angeles | $1,540 | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2025 |
| 2025-05-28 | CSL Behring | Childrens Hospital Los Angeles | $18 | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2025 |
| 2025-05-27 | Genentech, Inc. | Childrens Hospital Los Angeles | $12,831 | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2025 |
| 2025-04-21 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1,518 | NN7415-4307 | 2025 |
| 2025-04-21 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3,037 | NN7415-4307 | 2025 |
| 2025-04-14 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $315 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2025 |
| 2025-04-02 | SANOFI US SERVICES INC. | Childrens Hospital Los Angeles | $1,593 | A Phase 3 Open-label, Multicenter Study of the Long-term Safety and Efficacy of Intravenous Recombinant Coagulation Fact | 2025 |
| 2025-04-01 | Genentech, Inc. | Childrens Hospital Los Angeles | $4,182 | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2025 |
| 2025-03-14 | Genentech, Inc. | Childrens Hospital Los Angeles | $11,068 | STUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD of Emicuzumab in mild or moderate Hemophilia A NI | 2025 |
| 2025-03-12 | CSL Behring | Childrens Hospital Los Angeles | $15,480 | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2025 |
| 2025-02-10 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $2,109 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2025 |
| 2025-02-07 | CSL Behring | Childrens Hospital Los Angeles | $2,195 | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2025 |
| 2024-12-16 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $630 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2024 |
| 2024-12-09 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $2,454 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2024 |
| 2024-11-21 | CSL Behring | Childrens Hospital Los Angeles | $2,195 | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 |
| 2024-11-20 | BioMarin Pharmaceutical Inc. | Childrens Hospital Los Angeles | $2,548 | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | 2024 |
| 2024-11-20 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3,895 | NN7415-4807 | 2024 |
| 2024-11-20 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3,141 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-19 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $15 | NN7415-4807 | 2024 |
| 2024-11-06 | Novo Nordisk AS | Childrens Hospital Los Angeles | $9,875 | NN7415-4807 | 2024 |
| 2024-10-31 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1,127 | NN7415-4307 | 2024 |
| 2024-10-29 | BioMarin Pharmaceutical Inc. | Childrens Hospital Los Angeles | $1,197 | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | 2024 |
| 2024-10-29 | CSL Behring | Childrens Hospital Los Angeles | $122 | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 |
| 2024-10-21 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $2,448 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2024 |
| 2024-10-04 | BioMarin Pharmaceutical Inc. | Childrens Hospital Los Angeles | $2,395 | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | 2024 |
| 2024-09-23 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $3,714 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2024 |
| 2024-09-23 | GENZYME CORPORATION | Childrens Hospital Los Angeles | $2,244 | ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 1 | 2024 |
| 2024-09-20 | Novo Nordisk AS | Childrens Hospital Los Angeles | $2,635 | NN7415-4807 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-09-09 | Novo Nordisk AS | Childrens Hospital Los Angeles | $22 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-29 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1 | NN7415-4307 | 2024 |
| 2024-08-28 | Genentech, Inc. | Childrens Hospital Los Angeles | $1,540 | An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors | 2024 |
| 2024-08-23 | BioMarin Pharmaceutical Inc. | Childrens Hospital Los Angeles | $1,521 | Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors | 2024 |
| 2024-08-08 | CSL Behring | Childrens Hospital Los Angeles | $2,006 | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 |
| 2024-07-29 | CSL Behring | Childrens Hospital Los Angeles | $418 | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2024 |
| 2024-07-22 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1,127 | NN7415-4307 | 2024 |
| 2024-06-21 | Novo Nordisk AS | Childrens Hospital Los Angeles | $1,127 | NN7415-4307 | 2024 |
| 2024-06-21 | Novo Nordisk AS | Childrens Hospital Los Angeles | $13,487 | NN7415-4307 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $3 | NN7415-4807 | 2024 |
| 2024-06-13 | Novo Nordisk AS | Childrens Hospital Los Angeles | $12 | NN7415-4807 | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bozeman, MT, county Gallatin County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Bozeman, MT | County Gallatin County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 56,114 | 124,074 | 1,116,875 |
| Population, 2020 census P1 | 53,293 | 118,960 | 1,084,225 |
| Median age B01002 | 28.9 | 34.2 | 40.4 |
| Under 18 B01001 | 13.2% | 18.8% | 21.0% |
| 65 and over B01001 | 11.4% | 13.6% | 20.1% |
| Households B11001 | 23,970 | 51,215 | 458,859 |
| Foreign born B05002 | 4.8% | 4.1% | 2.3% |
| Median household income B19013 | $85,747 | $93,528 | $72,509 |
| Median family income B19113 | $117,132 | $117,341 | $92,794 |
| Per capita income B19301 | $52,507 | $54,482 | $41,711 |
| Poverty rate B17001 | 13.7% | 9.5% | 11.5% |
| Unemployment rate B23025 | 3.0% | 2.3% | 3.6% |
| Civilian labor force B23025 | 35,925 | 73,611 | 568,568 |
| Mean commute (minutes) B08013 | 15.5 | 18.3 | 19.1 |
| Bachelor's degree or higher B15003 | 65.1% | 54.3% | 35.2% |
| Housing units B25001 | 25,908 | 57,568 | 528,419 |
| Owner-occupied B25003 | 44.7% | 61.1% | 69.2% |
| Renters B25003 | 55.3% | 38.9% | 30.8% |
| Median home value B25077 | $687,900 | $667,600 | $375,800 |
| Median gross rent B25064 | $1,717 | $1,694 | $1,081 |
| White, not Hispanic B03002 | 84.8% | 87.5% | 83.6% |
| Black B03002 | 0.8% | 0.4% | 0.4% |
| Hispanic or Latino B03002 | 6.2% | 5.4% | 4.6% |
| Asian B03002 | 2.1% | 1.2% | 0.8% |
| American Indian and Alaska Native B03002 | 0.8% | 0.5% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bozeman, MT.
Comments